Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05639088
Other study ID # HM20024552
Secondary ID 1K23DK131368
Status Recruiting
Phase N/A
First received
Last updated
Start date August 24, 2023
Est. completion date January 1, 2026

Study information

Verified date April 2024
Source Virginia Commonwealth University
Contact Sarah Farthing
Phone 804-527-4756
Email sarah.malone@vcuhealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate a transition preparation program designed for adolescents and young adults (AYAs) with type 1 diabetes (T1D). This transition program will support AYAs as they prepare to transition from pediatric to adult endocrinology medical care and will also include a caregiver. Results from this study will inform clinical recommendations regarding self-management best practices for AYAs with T1D prior to transitioning to adult medical care.


Description:

Investigators will recruit adolescents and young adults ages 16-22 years with T1D and a parent/guardian. Families will participate in one of two 6-month treatments: 1) SHIFT2, engaging in monthly sessions with transition coaches providing education on diabetes management and healthcare transition, or 2) Enhanced treatment (TAU+), engaging in routine medical care and receiving monthly education (no coaches).


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date January 1, 2026
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: AYA: 1. Type 1 Diabetes diagnosis for at least 1 year (as documented in medical record) 2. 16-22 years old 3. English speaking 4. Children's Hospital of Richmond patient (Division of Pediatric Endocrinology) 5. must have a caregiver willing to participate Caregiver: 1. Age greater than 18 years 2. Provides care to AYA and willing to participate Exclusion Criteria: AYA: 1. Non-English speaking 2. Significant psychiatric, cognitive, medical or developmental conditions that would impair their ability to complete assessments and/or engage in diabetes self-care behaviors (e.g., malignancies, psychosis, intellectual disability 3. Hospitalization for depression, suicidal ideation or other psychiatric disorder within the past 12 months. Life time history of psychotic disorder 4. Medically-induced diabetes or diagnosis of diabetes other than type 1 diabetes. 5. Currently pregnant, pregnant within the past 6 months, currently breastfeeding or planning to become pregnant within the next 12 months. 6. Another member of the household (other than the participating parent) is a participant or staff member on this study. 7. Participation in another research study that may interfere with this study. 8. Previous participation in the SHIFT pilot study Caregiver: 1. Non-English speaking 2. Significant psychiatric, cognitive, developmental conditions that would impair their ability to complete assessments and/or engage in supporting the AYA with diabetes self-care behaviors (e.g., psychosis, intellectual disability) 3. Another member of the home (not AYA) is a participant/staff member on current study 4. Participation in another research study that may interfere with current study 5. Previous participation in SHIFT pilot study

Study Design


Intervention

Behavioral:
Transition preparation program
AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management. Caregivers will attend a virtual or in-person session with a transition coach.
Other:
Educational materials
AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
Virginia Commonwealth University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Transition Status AYAs that transition from pediatric to adult T1D care will be assessed. Baseline to 12 months
Primary Hemoglobin A1C (HbA1C) HbA1C will be assessed using a standard assay from a routine blood draw or an at-home testing kit 6 months
Primary Change in transition readiness Transition readiness will be measured using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) scale, which will be completed by AYAs. Baseline to 6 months
Primary Change in diabetes adherence Diabetes adherence will be assessed using the Self-Care Inventory-Revised, which will be completed by both AYA and caregivers. Baseline to 6 months
Primary Attendance at clinic visits Attendance at routine clinic visits will be determined from medical records and will be assessed by the number of regularly scheduled visits attended. 6 months
Secondary HbA1C HbA1C will be assessed using a standard assay from a routine blood draw or an at-home testing kit. 12 months
Secondary Diabetes-related events Number of diabetes-related events will be determined from medical records 12 months
Secondary Change in transition readiness Transition readiness will be measured using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) scale, which will be completed by AYAs. Baseline to 12 months
Secondary Change in diabetes adherence Diabetes adherence will be assessed using the Self-Care Inventory-Revised, which will be completed by both AYA and caregivers. Baseline to 12 months
Secondary Attendance at clinic visits Attendance at routine clinic visits will be determined from medical records. 12 months
Secondary Change in diabetes support Diabetes support will be assessed using the Diabetes Social Support Questionnaire - Family Version (DDSQ-Family), which will be completed by AYAs. Baseline to 12 months
Secondary Change in Diabetes Distress Diabetes distress will be assessed using the Diabetes Distress Scale (DDS) for Type 1 Diabetes (DDS), which will be completed by both AYA and caregivers. AYA will complete specific versions corresponding to age (>18 or <18) and caregivers complete their own version of the measure. Baseline to 12 months
Secondary Change in Self Efficacy Self-efficacy will be measured using the Self-efficacy for Diabetes Self-Management scale (SEDSM), which will be completed by AYAs. Baseline to 12 months
Secondary Change in Quality of Life Quality of life will be measured using the T1D and Life (T1DAL), which will be completed by AYA and caregiver. Baseline to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2